This work is conducted under the direction of Associate Professor Tarl Prow.
Description:This project builds on a novel cutaneous delivery method using elongate microparticles developed by A/Prof Prow at the The University of Queensland. He identified a need for enhanced field-directed topical drug delivery, not available with current topical delivery technologies. A/Prof Prow then developed unbound elongate microparticles that are mixed with the drug of interest and massaged onto the surface of the skin. The microparticles penetrate the skin, resulting in increased permeability and drug penetration.
Experiments in healthy volunteers have shown that the microparticles penetrate through the epidermis to the dermal-epidermal junction followed by natural removal from the skin through transepidermal elimination (skin turn-over).
However, diseased skin (e.g. skin cancer) has dramatically different physical, morphological and biological properties, in addition to the time for transepidermal turn-over. These factors are likely to influence the interaction of the microparticles within the skin. Furthermore, the therapies used for treating skin cancers, require multiple doses also resulting in significant changes to the skin. Understanding the interaction of the microparticles within non-lesional and lesional skin, in particular its penetration, delivery and elimination are a necessary step towards translating this technology to the clinic.
Aim of Study: A/Prof Prow's team is characterising the penetration/delivery/elimination of microparticles with different morphologies in volunteers with healthy and diseased skin. Through this we are identifying the role of the stratum corneum, viable epidermis and dermis in microparticle penetration.
Status:We have recruited and continue to recruit volunteers to study the Foroderm topical drug delivery enhancement platform in healthy and diseased skin.